Equity Overview
Price & Market Data
Price: $34.79
Daily Change: -$2.47 / 7.10%
Daily Range: $34.31 - $37.31
Market Cap: $1,562,151,168
Daily Volume: 420,091
Performance Metrics
1 Week: -8.45%
1 Month: -15.33%
3 Months: 31.98%
6 Months: 155.3%
1 Year: 194.1%
YTD: 10.30%
Company Details
Employees: 43
Sector: Health technology
Industry: Biotechnology
Country:
Details
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.